Transcription, replication, trafficking and assembly of the influenza virus RNA genome

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

September 29, 2028
Response Due
Active
Status

Opportunity Overview

Influenza viruses are important human and animal pathogens that have the potential to cause severe respiratory disease and death in humans. Influenza A and B viruses are responsible for seasonal epidemics and influenza A viruses also have the potential to cause pandemics. Influenza A viruses infect a wide range of animal species, with wild waterfowl being considered their natural reservoir. All four influenza A virus pandemics of recent human history occurred when either an avian influenza virus transmitted directly into the human population, giving rise to the 1918 pandemic, or avian or swine influenza viruses combined with human seasonal influenza virus, leading to the 1957, 1968 and 2009 pandemics. In the case of a new emerging influenza pandemic virus, no vaccines would be available initially and antivirals would be crucial to tackle the first wave of the virus; however, currently available influenza antivirals are limited.

The focus of our research programme is the RNA polymerase of influenza viruses, a large multifunctional enzyme complex. The function of the influenza virus RNA polymerase is to make copies of the genetic information of the virus, stored in segments of RNA. After an influenza virus infects a cell, the RNA polymerase first makes copies of the genetic material, which the cell is then 'forced' to read to make viral proteins, building blocks of new virus particles. The RNA polymerase also makes copies of the genetic material to be packed into new viruses and recent research suggests that it even plays a role in transporting the new genetic material to the sites in the cells where new virus particles are assembled. The RNA polymerase of influenza viruses is considered a prime viral target for the development of novel antiviral drugs; without it the virus is unable to make new copies of itself and spread to infect further hosts. Indeed, several polymerase inhibitors have been developed recently which are licensed for use in emergency in a limited...

This is one of 1,833 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedSeptember 30, 2023
Procurement stageActive solicitation
Response dueSeptember 29, 2028
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 09, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Targeting the circadian clock to restore hepatitis B T-cell immunity
The mechanistic basis for the ZAP antiviral system targeting viral and cellular RNAs
Health and Demographic Surveillance System
Exploiting cochlear hydrodynamics for uniform and non-invasive drug delivery along the entire intact cochlea
Identifying HLA-bespoke changes to CD4+ T cell epitopes in influenza A virus derived antigens to drive superior protective and heterotypic immunity
Mutagenesis and its biomedical consequences
CiliaScope - Transforming Respiratory Diagnostics With AI
Elucidating rotaviral condensate structure and function for future antiviral targeting

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.